Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy.

Vitzthum LK, Straka C, Sarkar RR, McKay R, Randall JM, Sandhu A, Murphy JD, Rose BS.

J Natl Compr Canc Netw. 2019 Dec;17(12):1497-1504. doi: 10.6004/jnccn.2019.7335.

PMID:
31805534
2.

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults.

Kumar A, Nalawade V, Riviere P, Sarkar RR, Parsons JK, Murphy JD, Rose BS.

JAMA Netw Open. 2019 Oct 2;2(10):e1913612. doi: 10.1001/jamanetworkopen.2019.13612. No abstract available.

3.

Tobacco smoking and death from prostate cancer in US veterans.

Riviere P, Kumar A, Luterstein E, Vitzthum LK, Nalawade V, Sarkar RR, Bryant AK, Einck JP, Mundt AJ, Murphy JD, Rose BS.

Prostate Cancer Prostatic Dis. 2019 Oct 17. doi: 10.1038/s41391-019-0178-6. [Epub ahead of print]

PMID:
31624316
4.

Benefits of Targeted Use of 5α-Reductase Inhibitors in Patients With Prostate Cancer-Reply.

Sarkar RR, Rose BS.

JAMA Intern Med. 2019 Oct 1;179(10):1442. doi: 10.1001/jamainternmed.2019.3890. No abstract available.

PMID:
31589266
5.

5α-Reductase Inhibitor Use in Patients With Prostate Cancer-Reply.

Sarkar RR, Rose BS.

JAMA Intern Med. 2019 Oct 1;179(10):1440-1441. doi: 10.1001/jamainternmed.2019.3620. No abstract available.

PMID:
31589264
6.

A Matched Case-Control Analysis of Clinical Outcomes for Patients With Inflammatory Bowel Disease and Rectal Cancer Treated With Pelvic Radiation Therapy.

Mudgway R, Bryant AK, Heide ES, Riviere P, O'Hare C, Rose BS, Murphy JD, Simpson DR.

Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):994-1004. doi: 10.1016/j.ijrobp.2019.08.023. Epub 2019 Aug 25.

PMID:
31461672
7.

Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer.

Sarkar RR, Bryant AK, Parsons JK, Ryan ST, Karim Kader A, Kane CJ, McKay RR, Sandhu A, Murphy JD, Rose BS.

Eur Urol Oncol. 2019 Sep;2(5):584-588. doi: 10.1016/j.euo.2018.09.015. Epub 2018 Oct 19.

PMID:
31411995
8.

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level.

Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):941-948. doi: 10.6004/jnccn.2018.7283.

PMID:
31390585
9.

Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.

Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, D'Amico AV, Nguyen PL, Hulley BJ, Einck JP, Mundt AJ, Kane CJ, Murphy JD, Rose BS.

JAMA Intern Med. 2019 Jun 1;179(6):812-819. doi: 10.1001/jamainternmed.2019.0280.

PMID:
31058923
10.

Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy.

Deka R, Simpson DR, Panizzon MS, Hauger RL, Riviere P, Nalawade V, McKay R, Murphy JD, Rose BS.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):600-608. doi: 10.1038/s41391-019-0150-5. Epub 2019 Apr 15.

PMID:
30988408
11.

In Reply to Hurmuz and Ozyigit.

Bryant AK, Rose BS.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):225. doi: 10.1016/j.ijrobp.2019.01.084. No abstract available.

PMID:
30967234
12.

Collision cross section compendium to annotate and predict multi-omic compound identities.

Picache JA, Rose BS, Balinski A, Leaptrot KL, Sherrod SD, May JC, McLean JA.

Chem Sci. 2018 Nov 27;10(4):983-993. doi: 10.1039/c8sc04396e. eCollection 2019 Jan 28.

13.

Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.

Deka R, Rose BS, Bryant AK, Sarkar RR, Nalawade V, McKay R, Murphy JD, Simpson DR.

Cancer. 2019 Apr 1;125(7):1070-1080. doi: 10.1002/cncr.31982. Epub 2019 Feb 12.

PMID:
30748008
14.

Postoperative radiation and hormonal therapy for men with node-positive prostate cancer: a new standard?

Rose BS.

BJU Int. 2019 Feb;123(2):199-200. doi: 10.1111/bju.14501. No abstract available.

PMID:
30656836
15.

Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer.

Bryant AK, McKay RR, Kader AK, Parsons JK, Einck JP, Kane CJ, Mundt AJ, Murphy JD, Rose BS.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1068-1076. doi: 10.1016/j.ijrobp.2018.12.001. Epub 2018 Dec 11.

PMID:
30543857
16.

Detecting a Survival Benefit to Dose Escalation.

Zakeri K, Rose BS, Mell LK.

JAMA Oncol. 2019 Jan 1;5(1):109-110. doi: 10.1001/jamaoncol.2018.5055. No abstract available.

17.

Untargeted Molecular Discovery in Primary Metabolism: Collision Cross Section as a Molecular Descriptor in Ion Mobility-Mass Spectrometry.

Nichols CM, Dodds JN, Rose BS, Picache JA, Morris CB, Codreanu SG, May JC, Sherrod SD, McLean JA.

Anal Chem. 2018 Dec 18;90(24):14484-14492. doi: 10.1021/acs.analchem.8b04322. Epub 2018 Nov 30.

18.

Association of Androgen Deprivation Therapy With Dementia in Men With Prostate Cancer Who Receive Definitive Radiation Therapy.

Deka R, Simpson DR, Bryant AK, Nalawade V, McKay R, Murphy JD, Rose BS.

JAMA Oncol. 2018 Nov 1;4(11):1616-1617. doi: 10.1001/jamaoncol.2018.4423. No abstract available.

19.

Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.

Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ, Kane CJ, Efstathiou JA, Murphy JD, Rose BS.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1188-1193. doi: 10.1016/j.ijrobp.2018.04.023. Epub 2018 Apr 17.

PMID:
29891203
20.

Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.

Bryant AK, D'Amico AV, Nguyen PL, Einck JP, Kane CJ, McKay RR, Simpson DR, Mundt AJ, Murphy JD, Rose BS.

Cancer. 2018 Jul 15;124(14):2939-2947. doi: 10.1002/cncr.31400. Epub 2018 May 4.

21.

Who benefits most from early salvage radiation therapy after prostatectomy?

Nath SK, Rose BS, Pugh TJ.

Transl Androl Urol. 2018 Mar;7(Suppl 1):S124-S127. doi: 10.21037/tau.2017.11.23. No abstract available.

22.

Reply to S. Sorscher.

Rose BS, Winer EP, Mamon HJ.

J Clin Oncol. 2017 May 20;35(15):1746-1747. doi: 10.1200/JCO.2017.72.2876. Epub 2017 Mar 6. No abstract available.

PMID:
28524778
23.

Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer.

Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF 3rd, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL.

Clin Genitourin Cancer. 2017 Oct;15(5):563-569.e3. doi: 10.1016/j.clgc.2016.10.011. Epub 2016 Oct 28.

PMID:
28462857
24.

Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.

Rose BS, Chen MH, Wu J, Braccioforte MH, Moran BJ, Doseretz DE, Katin MJ, Ross RH, Salenius SA, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):778-784. doi: 10.1016/j.ijrobp.2016.08.014. Epub 2016 Aug 22.

PMID:
27788950
25.

Perils of the Pathologic Complete Response.

Rose BS, Winer EP, Mamon HJ.

J Clin Oncol. 2016 Nov 20;34(33):3959-3962. doi: 10.1200/JCO.2016.68.1718. Epub 2016 Oct 31. No abstract available.

PMID:
27551115
26.

Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?

Muralidhar V, Rose BS, Chen YW, Nezolosky MD, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):313-317. doi: 10.1016/j.ijrobp.2016.05.022. Epub 2016 May 27.

PMID:
27496390
27.

Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.

Rose BS, Jee KW, Niemierko A, Murphy JE, Blaszkowsky LS, Allen JN, Lee LK, Wang Y, Drapek LC, Hong TS, Wo JY.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):747-54. doi: 10.1016/j.ijrobp.2015.12.006. Epub 2015 Dec 17.

PMID:
26972647
28.

Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events.

Carmona R, Zakeri K, Green G, Hwang L, Gulaya S, Xu B, Verma R, Williamson CW, Triplett DP, Rose BS, Shen H, Vaida F, Murphy JD, Mell LK.

J Clin Oncol. 2016 Apr 10;34(11):1270-7. doi: 10.1200/JCO.2015.65.0739. Epub 2016 Feb 16.

29.

Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer.

Rose BS, Jiang W, Punglia RS.

Breast Cancer Res Treat. 2015 Jul;152(1):209-216. doi: 10.1007/s10549-015-3451-y. Epub 2015 Jun 4.

PMID:
26041688
30.

Competing events and costs of clinical trials: Analysis of a randomized trial in prostate cancer.

Zakeri K, Rose BS, D'Amico AV, Jeong JH, Mell LK.

Radiother Oncol. 2015 Apr;115(1):114-9. doi: 10.1016/j.radonc.2015.03.018. Epub 2015 Apr 6.

31.

Complications of pelvic radiation in patients treated for gynecologic malignancies.

Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, Rose BS, von Keudell AG, Wo JY.

Cancer. 2014 Dec 15;120(24):3870-83. doi: 10.1002/cncr.28849. Epub 2014 Jul 23. Review.

32.

Validated competing event model for the stage I-II endometrial cancer population.

Carmona R, Gulaya S, Murphy JD, Rose BS, Wu J, Noticewala S, McHale MT, Yashar CM, Vaida F, Mell LK.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):888-98. doi: 10.1016/j.ijrobp.2014.03.047.

PMID:
24969798
33.

Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy.

Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV.

Clin Genitourin Cancer. 2014 Oct;12(5):e173-9. doi: 10.1016/j.clgc.2014.03.008. Epub 2014 Mar 28.

PMID:
24787967
34.

On lumping, splitting, and the nosology of clinical trial populations and end points.

Mell LK, Zakeri K, Rose BS.

J Clin Oncol. 2014 Apr 1;32(10):1089-90. doi: 10.1200/JCO.2013.54.4429. Epub 2014 Feb 18. No abstract available.

35.

Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin.

Jensen LG, Hasselle MD, Rose BS, Nath SK, Hasan Y, Scanderbeg DJ, Yashar CM, Mundt AJ, Mell LK.

Int J Gynecol Cancer. 2013 Jan;23(1):119-25. doi: 10.1097/IGC.0b013e3182749114.

PMID:
23262521
36.

Cardiovascular and behavioral response to auditory stimuli in boys with fragile X syndrome.

Roberts JE, Long AC, McCary LM, Quady AN, Rose BS, Widrick D, Baranek G.

J Pediatr Psychol. 2013 Apr;38(3):276-84. doi: 10.1093/jpepsy/jss114. Epub 2012 Nov 11.

37.

Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794.

Zakeri K, Rose BS, Gulaya S, D'Amico AV, Mell LK.

Contemp Clin Trials. 2013 Jan;34(1):74-9. doi: 10.1016/j.cct.2012.09.008. Epub 2012 Oct 11.

38.

Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.

Liang Y, Bydder M, Yashar CM, Rose BS, Cornell M, Hoh CK, Lawson JD, Einck J, Saenz C, Fanta P, Mundt AJ, Bydder GM, Mell LK.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):406-14. doi: 10.1016/j.ijrobp.2012.04.044. Epub 2012 Jun 9.

PMID:
22687195
39.

Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: a systematic review.

Mell LK, Lau SK, Rose BS, Jeong JH.

Contemp Clin Trials. 2012 Sep;33(5):920-4. doi: 10.1016/j.cct.2012.05.013. Epub 2012 Jun 1. Review.

PMID:
22664646
40.

Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.

Simpson DR, Song WY, Moiseenko V, Rose BS, Yashar CM, Mundt AJ, Mell LK.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e81-6. doi: 10.1016/j.ijrobp.2011.12.012.

PMID:
22516388
41.

Clinical practice patterns of lung stereotactic body radiation therapy in the United States: a secondary analysis.

Pan H, Rose BS, Simpson DR, Mell LK, Mundt AJ, Lawson JD.

Am J Clin Oncol. 2013 Jun;36(3):269-72. doi: 10.1097/COC.0b013e3182467db3.

42.

Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

Rose BS, Liang Y, Lau SK, Jensen LG, Yashar CM, Hoh CK, Mell LK.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1185-91. doi: 10.1016/j.ijrobp.2011.09.048. Epub 2012 Jan 21.

PMID:
22270171
43.

Population-based study of competing mortality in head and neck cancer.

Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK.

J Clin Oncol. 2011 Sep 10;29(26):3503-9. doi: 10.1200/JCO.2011.35.7301. Epub 2011 Aug 15.

PMID:
21844503
44.

Observed magnetic resonance imaging changes in pediatric patients treated with stereotactic radiosurgery for intracranial tumors.

Nath SK, Carmona R, Rose BS, Simpson DR, Russell M, Lawson JD, Mundt AJ, Murphy KT.

Childs Nerv Syst. 2011 Mar;27(3):399-406. doi: 10.1007/s00381-010-1288-6. Epub 2010 Oct 7.

45.

Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix.

Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, Hasan Y, Roeske JC, Mundt AJ, Mell LK.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1436-45. doi: 10.1016/j.ijrobp.2010.04.041. Epub 2010 Aug 12.

PMID:
20708346
46.

Recurrent metachronous acute compartment syndrome in the legs of a child.

Ogunlusi JD, George RS, Rose BS.

West Afr J Med. 2010 May-Jun;29(3):190-2.

PMID:
20665465
47.

A survey of image-guided radiation therapy use in the United States.

Simpson DR, Lawson JD, Nath SK, Rose BS, Mundt AJ, Mell LK.

Cancer. 2010 Aug 15;116(16):3953-60. doi: 10.1002/cncr.25129.

48.

Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data.

Liang Y, Messer K, Rose BS, Lewis JH, Jiang SB, Yashar CM, Mundt AJ, Mell LK.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):912-9. doi: 10.1016/j.ijrobp.2009.11.062. Epub 2010 May 14.

49.

Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

Rose BS, Aydogan B, Liang Y, Yeginer M, Hasselle MD, Dandekar V, Bafana R, Yashar CM, Mundt AJ, Roeske JC, Mell LK.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):800-7. doi: 10.1016/j.ijrobp.2009.11.010. Epub 2010 Apr 17.

50.

Utilization of advanced imaging technologies for target delineation in radiation oncology.

Simpson DR, Lawson JD, Nath SK, Rose BS, Mundt AJ, Mell LK.

J Am Coll Radiol. 2009 Dec;6(12):876-83. doi: 10.1016/j.jacr.2009.08.006.

PMID:
19945044

Supplemental Content

Support Center